Short answer
Harmony Biosciences Holdings, Inc. (HRMY) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
Harmony Biosciences Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 4, 2026
- Detailed financial results and management commentary in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Investor presentation posted August 4, 2026, providing management’s latest messaging for investors and analysts
- Exhibit 99.2 contains the substantive business, strategy and outlook disclosures
- Presentation includes forward-looking statements subject to material execution and regulatory risks
- Disclosure is furnished, not filed, limiting liability and automatic incorporation into future SEC filings
Item EX-99.1 · Exhibit EX-99.1
- Q2 WAKIX revenue $261.3M, up 30% year over year; average patients rose 450 to 8,950
- 2026 WAKIX revenue guidance reiterated at $1.0B-$1.04B, supporting continued commercial momentum
- Net income $75.4M, or $1.28 diluted EPS, versus $39.8M and $0.68 in Q2 2025
- Gross-margin pressure: cost of product sold reached 24.2% of revenue versus 19.0%, driven by Novitium royalties
- BP-205 Phase 1 data showed approximately 25-hour half-life and no serious or severe adverse events; Phase 2 planned for mid-2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Harmony Biosciences Holdings, Inc. 8-K filings
Get the next HRMY 8-K as it lands
Follow HRMY for push alerts, or ask the research agent what this filing means.